Spontaneous development of myasthenia gravis and myositis following treatment with pembrolizumab: a case report
Abstract Background Immune checkpoint inhibitors are a relatively new advancement in the world of cancer therapy. As such, their adverse effects have yet to be fully understood, with only recent literature documenting autoimmune phenomena secondary to their utilization. Specific immune checkpoint in...
Salvato in:
| Autori principali: | , , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BMC
2024-06-01
|
| Serie: | BMC Neurology |
| Soggetti: | |
| Accesso online: | https://doi.org/10.1186/s12883-024-03684-2 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|